These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26026252)

  • 1. Stabilisation of amorphous furosemide increases the oral drug bioavailability in rats.
    Nielsen LH; Rades T; Müllertz A
    Int J Pharm; 2015 Jul; 490(1-2):334-40. PubMed ID: 26026252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster Tmax after oral dosing to rats.
    Nielsen LH; Gordon S; Holm R; Selen A; Rades T; Müllertz A
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):942-51. PubMed ID: 24075980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymeric microcontainers improve oral bioavailability of furosemide.
    Nielsen LH; Melero A; Keller SS; Jacobsen J; Garrigues T; Rades T; Müllertz A; Boisen A
    Int J Pharm; 2016 May; 504(1-2):98-109. PubMed ID: 27033999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound.
    Tong HH; Du Z; Wang GN; Chan HM; Chang Q; Lai LC; Chow AH; Zheng Y
    Int J Pharm; 2011 Feb; 404(1-2):148-58. PubMed ID: 21094233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the effect of spray drying and hot-melt extrusion on the properties of amorphous solid dispersions containing felodipine.
    Mahmah O; Tabbakh R; Kelly A; Paradkar A
    J Pharm Pharmacol; 2014 Feb; 66(2):275-84. PubMed ID: 24433426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
    Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
    Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique.
    Marasini N; Tran TH; Poudel BK; Cho HJ; Choi YK; Chi SC; Choi HG; Yong CS; Kim JO
    Int J Pharm; 2013 Jan; 441(1-2):424-32. PubMed ID: 23174408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in-vitro pH-dissolution dependence and in-vivo bioavailability of frusemide-PVP solid dispersions.
    Doherty C; York P
    J Pharm Pharmacol; 1989 Feb; 41(2):73-8. PubMed ID: 2568431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of amorphous phase separation and crystallization on the in vitro and in vivo performance of an amorphous solid dispersion.
    Knopp MM; Wendelboe J; Holm R; Rades T
    Eur J Pharm Biopharm; 2018 Sep; 130():290-295. PubMed ID: 30064702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amorphization within the tablet: Using microwave irradiation to form a glass solution in situ.
    Doreth M; Hussein MA; Priemel PA; Grohganz H; Holm R; Lopez de Diego H; Rades T; Löbmann K
    Int J Pharm; 2017 Mar; 519(1-2):343-351. PubMed ID: 28115260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
    Caron V; Tajber L; Corrigan OI; Healy AM
    Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib:PVP amorphous solid dispersions.
    Knopp MM; Nguyen JH; Becker C; Francke NM; Jørgensen EB; Holm P; Holm R; Mu H; Rades T; Langguth P
    Eur J Pharm Biopharm; 2016 Apr; 101():145-51. PubMed ID: 26899127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs.
    Nkansah P; Antipas A; Lu Y; Varma M; Rotter C; Rago B; El-Kattan A; Taylor G; Rubio M; Litchfield J
    J Control Release; 2013 Jul; 169(1-2):150-61. PubMed ID: 23570985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability.
    Ochi M; Kimura K; Kanda A; Kawachi T; Matsuda A; Yuminoki K; Hashimoto N
    AAPS PharmSciTech; 2016 Aug; 17(4):932-9. PubMed ID: 27435198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.
    Rasool BK; Fahmy SA; Galeel OW
    Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of supercritical fluids to enhance the dissolution behaviors of Furosemide by generation of microparticles and solid dispersions.
    De Zordi N; Moneghini M; Kikic I; Grassi M; Del Rio Castillo AE; Solinas D; Bolger MB
    Eur J Pharm Biopharm; 2012 May; 81(1):131-41. PubMed ID: 22266263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent.
    Tran TH; Poudel BK; Marasini N; Chi SC; Choi HG; Yong CS; Kim JO
    Int J Pharm; 2013 Feb; 443(1-2):50-7. PubMed ID: 23318367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilization of low glass transition temperature indomethacin formulations: impact of polymer-type and its concentration.
    Chokshi RJ; Shah NH; Sandhu HK; Malick AW; Zia H
    J Pharm Sci; 2008 Jun; 97(6):2286-98. PubMed ID: 17879977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and stability of solid dispersions based on PEG/polymer blends.
    Bley H; Fussnegger B; Bodmeier R
    Int J Pharm; 2010 May; 390(2):165-73. PubMed ID: 20132875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing the bioavailability of magnolol in rabbits using melting solid dispersion with polyvinylpyrrolidone.
    Lin SP; Hou YC; Liao TY; Tsai SY
    Drug Dev Ind Pharm; 2014 Mar; 40(3):330-7. PubMed ID: 23369092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.